Lurbinectedin

(Zepzelca®)

Zepzelca®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 4 mg)
Drug ClassAlkylating agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Lurbinectedin (Zepzelca) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression on or after platinum-based chemotherapy.
  • Two studies were reviewed to gather information about this medication. The first study evaluated various treatments for relapsed SCLC, while the second compared lurbinectedin to other second-line treatments specifically in platinum-sensitive patients.
  • According to these studies, many current treatments show uncertain clinical potential due to issues such as lack of randomization and small sample sizes. This observation highlights a significant unmet need within the field of relapsed SCLC treatment.
  • Lurbinectedin demonstrates significant survival benefits over oral and IV topotecan and platinum re-challenge in treating metastatic SCLC. It also has a favorable safety profile according to hazard ratios indicating a reduced risk of death compared to these treatments.
  • Specifically among platinum-sensitive patients, lurbinectedin appears superior based on its effectiveness and safety profile. This suggests that it may fill a critical gap for this subgroup within the challenging therapeutic area of relapsed SCLC treatment.
  • Despite promising results from phase 2 data regarding certain medications like tyrosine kinase inhibitors (TKIs), more phase 3 trials are needed, especially comparing lurbinectedin with standard treatments, in order to better define its position in the treatment paradigm for SCLC.

Product Monograph / Prescribing Information

Document TitleYearSource
Zepzelca (lurbinectedin) Prescribing Information.2023Jazz Pharmaceuticals, Inc., Palo Alto, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
SEOM clinical guidelines for the treatment of small‑cell lung cancer (SCLC) (2019).2020Clinical and Translational Oncology